Compare W & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | W | EXEL |
|---|---|---|
| Founded | 2002 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9B | 11.7B |
| IPO Year | 2014 | 2000 |
| Metric | W | EXEL |
|---|---|---|
| Price | $79.58 | $41.76 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 28 | 21 |
| Target Price | ★ $105.82 | $46.45 |
| AVG Volume (30 Days) | ★ 3.7M | 2.7M |
| Earning Date | 05-22-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 39.15 | ★ 57.95 |
| EPS | N/A | ★ 2.78 |
| Revenue | N/A | ★ $452,477,000.00 |
| Revenue This Year | $7.39 | $13.66 |
| Revenue Next Year | $6.00 | $13.73 |
| P/E Ratio | ★ N/A | $15.12 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.41 | $32.38 |
| 52 Week High | $119.98 | $48.74 |
| Indicator | W | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 46.66 | 46.23 |
| Support Level | $70.59 | $40.01 |
| Resistance Level | $82.72 | $44.15 |
| Average True Range (ATR) | 4.17 | 1.23 |
| MACD | 1.28 | -0.08 |
| Stochastic Oscillator | 69.50 | 39.62 |
Wayfair engages in e-commerce in the United States (88% of 2025 sales), Canada, the United Kingdom, and Ireland. It's also embarked on expansion into the brick-and-mortar landscape, with 12 stores (excluding outlets) between the AllModern, Birch Lane, Joss & Main, and Wayfair banners. At the end of 2025, the firm offered more than 40 million products from more than 20,000 suppliers under the brands Wayfair, Joss & Main, AllModern, Birch Lane, and Perigold. Its offerings include furniture, everyday and seasonal decor, decorative accents, housewares, as well as advertising and logistics services. Wayfair was founded in 2002 and began trading publicly in 2014.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.